{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,17]],"date-time":"2026-11-17T08:42:41Z","timestamp":1794904961174,"version":"4.9.1"},"reference-count":134,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,7,29]],"date-time":"2024-07-29T00:00:00Z","timestamp":1722211200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["thelancet.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Lancet Healthy Longevity"],"published-print":{"date-parts":[[2024,10]]},"DOI":"10.1016\/j.lanhl.2024.07.013","type":"journal-article","created":{"date-parts":[[2024,10,3]],"date-time":"2024-10-03T18:33:49Z","timestamp":1727980429000},"page":"100630","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":154,"title":["Challenges in the practical implementation of blood biomarkers for Alzheimer\u2019s disease"],"prefix":"10.1016","volume":"5","author":[{"given":"Michael","family":"Sch\u00f6ll","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Inge M W","family":"Verberk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marta","family":"del Campo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8606-6814","authenticated-orcid":false,"given":"Constance","family":"Delaby","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph","family":"Therriault","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joyce R","family":"Chong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sebastian","family":"Palmqvist","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3819-3245","authenticated-orcid":false,"given":"Daniel","family":"Alcolea","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.lanhl.2024.07.013_bib1","first-page":"659","article-title":"Current diagnostic pathways for Alzheimer\u2019s disease: a cross-sectional real-world study across six countries","volume":"7","author":"Roth","year":"2023","journal-title":"J\u00a0Alzheimers Dis Rep"},{"key":"10.1016\/j.lanhl.2024.07.013_bib2","doi-asserted-by":"crossref","first-page":"5805","DOI":"10.1002\/alz.13455","article-title":"The potential clinical value of plasma biomarkers in Alzheimer\u2019s disease","volume":"19","author":"Blennow","year":"2023","journal-title":"Alzheimers Dement"},{"key":"10.1016\/j.lanhl.2024.07.013_bib3","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1212\/WNL.0000000000207193","article-title":"Blood biomarkers in neurodegenerative diseases: implications for the clinical neurologist","volume":"101","author":"Alcolea","year":"2023","journal-title":"Neurology"},{"key":"10.1016\/j.lanhl.2024.07.013_bib4","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1016\/S1474-4422(20)30071-5","article-title":"Blood phosphorylated tau 181\u00a0as a biomarker for Alzheimer\u2019s disease: a diagnostic performance and prediction modelling study using data from four prospective cohorts","volume":"19","author":"Karikari","year":"2020","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.lanhl.2024.07.013_bib5","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1001\/jamaneurol.2023.5319","article-title":"Diagnostic accuracy of a plasma phosphorylated tau 217\u00a0immunoassay for Alzheimer disease pathology","volume":"81","author":"Ashton","year":"2024","journal-title":"JAMA Neurol"},{"key":"10.1016\/j.lanhl.2024.07.013_bib6","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1001\/jama.2020.12134","article-title":"Discriminative accuracy of plasma phospho-tau217 for Alzheimer disease vs other neurodegenerative disorders","volume":"324","author":"Palmqvist","year":"2020","journal-title":"JAMA"},{"key":"10.1016\/j.lanhl.2024.07.013_bib7","doi-asserted-by":"crossref","first-page":"1471","DOI":"10.1001\/jamaneurol.2021.3671","article-title":"Differences between plasma and cerebrospinal fluid glial fibrillary acidic protein levels across the Alzheimer disease continuum","volume":"78","author":"Benedet","year":"2021","journal-title":"JAMA Neurol"},{"key":"10.1016\/j.lanhl.2024.07.013_bib8","doi-asserted-by":"crossref","first-page":"1034","DOI":"10.1038\/s41591-021-01348-z","article-title":"Prediction of future Alzheimer\u2019s disease dementia using plasma phospho-tau combined with other accessible measures","volume":"27","author":"Palmqvist","year":"2021","journal-title":"Nat Med"},{"key":"10.1016\/j.lanhl.2024.07.013_bib9","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1038\/nature25456","article-title":"High performance plasma amyloid-\u03b2 biomarkers for Alzheimer\u2019s disease","volume":"554","author":"Nakamura","year":"2018","journal-title":"Nature"},{"key":"10.1016\/j.lanhl.2024.07.013_bib10","doi-asserted-by":"crossref","first-page":"1225","DOI":"10.1002\/alz.13539","article-title":"Modeling the temporal evolution of plasma p-tau in relation to amyloid beta and tau PET","volume":"20","author":"Cogswell","year":"2024","journal-title":"Alzheimers Dement"},{"key":"10.1016\/j.lanhl.2024.07.013_bib11","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1097\/YCO.0000000000000851","article-title":"Plasma biomarkers for neurodegenerative disorders: ready for prime time?","volume":"36","author":"Balogun","year":"2023","journal-title":"Curr Opin Psychiatry"},{"key":"10.1016\/j.lanhl.2024.07.013_bib12","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1038\/s43587-023-00471-5","article-title":"A\u00a0two-step workflow based on\u00a0plasma p-tau217 to screen for amyloid \u03b2 positivity with further confirmatory testing only in uncertain cases","volume":"3","author":"Brum","year":"2023","journal-title":"Nat Aging"},{"key":"10.1016\/j.lanhl.2024.07.013_bib13","doi-asserted-by":"crossref","DOI":"10.1002\/alz.13859","article-title":"Revised criteria for diagnosis and staging of Alzheimer\u2019s disease: Alzheimer\u2019s Association workgroup","author":"Jack","year":"2024","journal-title":"Alzheimers Dement"},{"key":"10.1016\/j.lanhl.2024.07.013_bib14","doi-asserted-by":"crossref","first-page":"1375","DOI":"10.1001\/jamaneurol.2021.3180","article-title":"Head-to-head comparison of 8\u00a0plasma amyloid-\u03b242\/40 assays in Alzheimer disease","volume":"78","author":"Janelidze","year":"2021","journal-title":"JAMA Neurol"},{"key":"10.1016\/j.lanhl.2024.07.013_bib15","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1186\/s13195-021-00911-7","article-title":"Performance of the plasma A\u03b242\/A\u03b240\u00a0ratio, measured with a novel HPLC-MS\/MS method, as a biomarker of amyloid PET status in a DPUK-KOREAN cohort","volume":"13","author":"Jang","year":"2021","journal-title":"Alzheimers Res Ther"},{"key":"10.1016\/j.lanhl.2024.07.013_bib16","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1186\/s13195-022-01143-z","article-title":"Clinical performance of an antibody-free assay for plasma A\u03b242\/A\u03b240\u00a0to detect early alterations of Alzheimer\u2019s disease in individuals with subjective cognitive decline","volume":"15","author":"Pascual-Lucas","year":"2023","journal-title":"Alzheimers Res Ther"},{"key":"10.1016\/j.lanhl.2024.07.013_bib17","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1186\/s13195-022-01117-1","article-title":"The performance of plasma amyloid beta measurements in identifying amyloid plaques in Alzheimer\u2019s disease: a literature review","volume":"14","author":"Brand","year":"2022","journal-title":"Alzheimers Res Ther"},{"key":"10.1016\/j.lanhl.2024.07.013_bib18","doi-asserted-by":"crossref","first-page":"1592","DOI":"10.1093\/brain\/awac333","article-title":"Head-to-head comparison of 10\u00a0plasma phospho-tau assays in prodromal Alzheimer\u2019s disease","volume":"146","author":"Janelidze","year":"2023","journal-title":"Brain"},{"key":"10.1016\/j.lanhl.2024.07.013_bib19","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1016\/S1474-4422(22)00168-5","article-title":"Tau biomarkers in Alzheimer\u2019s disease: towards implementation in clinical practice and trials","volume":"21","author":"Ossenkoppele","year":"2022","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.lanhl.2024.07.013_bib20","doi-asserted-by":"crossref","first-page":"2029","DOI":"10.1093\/brain\/awad042","article-title":"Predicting amyloid PET and tau PET stages with plasma biomarkers","volume":"146","author":"Jack","year":"2023","journal-title":"Brain"},{"key":"10.1016\/j.lanhl.2024.07.013_bib21","doi-asserted-by":"crossref","DOI":"10.1084\/jem.20200861","article-title":"Blood plasma phosphorylated-tau isoforms track CNS change in Alzheimer\u2019s disease","volume":"217","author":"Barth\u00e9lemy","year":"2020","journal-title":"J\u00a0Exp Med"},{"key":"10.1016\/j.lanhl.2024.07.013_bib22","doi-asserted-by":"crossref","first-page":"1913","DOI":"10.1002\/alz.12841","article-title":"Plasma and CSF biomarkers in a memory clinic: head-to-head comparison of phosphorylated tau immunoassays","volume":"19","author":"Ashton","year":"2023","journal-title":"Alzheimers Dement"},{"key":"10.1016\/j.lanhl.2024.07.013_bib23","doi-asserted-by":"crossref","first-page":"4967","DOI":"10.1002\/alz.13026","article-title":"Equivalence of plasma p-tau217 with cerebrospinal fluid in the diagnosis of Alzheimer\u2019s disease","volume":"19","author":"Therriault","year":"2023","journal-title":"Alzheimers Dement"},{"key":"10.1016\/j.lanhl.2024.07.013_bib24","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.1038\/s41591-024-02869-z","article-title":"Highly accurate blood test for Alzheimer\u2019s disease is similar or superior to clinical cerebrospinal fluid tests","volume":"30","author":"Barth\u00e9lemy","year":"2024","journal-title":"Nat Med"},{"key":"10.1016\/j.lanhl.2024.07.013_bib25","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1007\/s00401-021-02275-6","article-title":"Plasma p-tau231: a new biomarker for incipient Alzheimer\u2019s disease pathology","volume":"141","author":"Ashton","year":"2021","journal-title":"Acta Neuropathol"},{"key":"10.1016\/j.lanhl.2024.07.013_bib26","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1038\/s41582-024-00942-2","article-title":"Biomarker-based staging of Alzheimer disease: rationale and clinical applications","volume":"20","author":"Therriault","year":"2024","journal-title":"Nat Rev Neurol"},{"key":"10.1016\/j.lanhl.2024.07.013_bib27","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1038\/s43587-023-00405-1","article-title":"Mass spectrometric simultaneous quantification of tau species in plasma shows differential associations with amyloid and tau pathologies","volume":"3","author":"Montoliu-Gaya","year":"2023","journal-title":"Nat Aging"},{"key":"10.1016\/j.lanhl.2024.07.013_bib28","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1007\/s00401-023-02659-w","article-title":"CSF p-tau205: a biomarker of tau pathology in Alzheimer\u2019s disease","volume":"147","author":"Lantero-Rodriguez","year":"2024","journal-title":"Acta Neuropathol"},{"key":"10.1016\/j.lanhl.2024.07.013_bib29","doi-asserted-by":"crossref","first-page":"3400","DOI":"10.1038\/s41467-021-23620-z","article-title":"A\u00a0multicentre validation study of the diagnostic value of plasma neurofilament light","volume":"12","author":"Ashton","year":"2021","journal-title":"Nat Commun"},{"key":"10.1016\/j.lanhl.2024.07.013_bib30","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1186\/s13195-018-0404-9","article-title":"Plasma neurofilament light as a potential biomarker of neurodegeneration in Alzheimer\u2019s disease","volume":"10","author":"Lewczuk","year":"2018","journal-title":"Alzheimers Res Ther"},{"key":"10.1016\/j.lanhl.2024.07.013_bib31","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1001\/jamaneurol.2016.6117","article-title":"Alzheimer\u2019s Disease Neuroimaging Initiative. Association of plasma neurofilament light with neurodegeneration in patients with Alzheimer disease","volume":"74","author":"Mattsson","year":"2017","journal-title":"JAMA Neurol"},{"key":"10.1016\/j.lanhl.2024.07.013_bib32","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1016\/S1474-4422(18)30285-0","article-title":"Plasma and CSF biomarkers for the diagnosis of Alzheimer\u2019s disease in adults with Down syndrome: a cross-sectional study","volume":"17","author":"Fortea","year":"2018","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.lanhl.2024.07.013_bib33","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1016\/S1474-4422(21)00129-0","article-title":"Diagnostic and prognostic performance and longitudinal changes in plasma neurofilament light chain concentrations in adults with Down syndrome: a cohort study","volume":"20","author":"Carmona-Iragui","year":"2021","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.lanhl.2024.07.013_bib34","doi-asserted-by":"crossref","first-page":"1152","DOI":"10.1093\/brain\/awac407","article-title":"Brain-derived tau: a novel blood-based biomarker for Alzheimer\u2019s disease-type neurodegeneration","volume":"146","author":"Gonzalez-Ortiz","year":"2023","journal-title":"Brain"},{"key":"10.1016\/j.lanhl.2024.07.013_bib35","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1002\/ana.26360","article-title":"Serum beta-synuclein is higher in Down syndrome and precedes rise of pTau181","volume":"92","author":"Oeckl","year":"2022","journal-title":"Ann Neurol"},{"key":"10.1016\/j.lanhl.2024.07.013_bib36","doi-asserted-by":"crossref","first-page":"5095","DOI":"10.1002\/alz.13103","article-title":"Higher plasma \u03b2-synuclein indicates early synaptic degeneration in Alzheimer\u2019s disease","volume":"19","author":"Oeckl","year":"2023","journal-title":"Alzheimers Dement"},{"key":"10.1016\/j.lanhl.2024.07.013_bib37","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1186\/s13195-022-01125-1","article-title":"\u03b2-synuclein as a candidate blood biomarker for synaptic degeneration in Alzheimer\u2019s disease","volume":"14","author":"Mohaupt","year":"2022","journal-title":"Alzheimers Res Ther"},{"key":"10.1016\/j.lanhl.2024.07.013_bib38","doi-asserted-by":"crossref","first-page":"1310","DOI":"10.1021\/acs.jproteome.9b00824","article-title":"Targeted mass spectrometry suggests beta-synuclein as synaptic blood marker in Alzheimer\u2019s disease","volume":"19","author":"Oeckl","year":"2020","journal-title":"J\u00a0Proteome Res"},{"key":"10.1016\/j.lanhl.2024.07.013_bib39","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.3390\/cells12091309","article-title":"GFAP as a potential biomarker for Alzheimer\u2019s disease: a systematic review and meta-analysis","volume":"12","author":"Kim","year":"2023","journal-title":"Cells"},{"key":"10.1016\/j.lanhl.2024.07.013_bib40","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1016\/j.jalz.2019.09.004","article-title":"Plasma biomarkers of astrocytic and neuronal dysfunction in early- and late-onset Alzheimer\u2019s disease","volume":"16","author":"Elahi","year":"2020","journal-title":"Alzheimers Dement"},{"key":"10.1016\/j.lanhl.2024.07.013_bib41","doi-asserted-by":"crossref","first-page":"3505","DOI":"10.1093\/brain\/awab223","article-title":"Plasma GFAP is an early marker of amyloid-\u03b2 but not tau pathology in Alzheimer\u2019s disease","volume":"144","author":"Pereira","year":"2021","journal-title":"Brain"},{"key":"10.1016\/j.lanhl.2024.07.013_bib42","doi-asserted-by":"crossref","DOI":"10.1016\/j.ebiom.2023.104547","article-title":"Plasma and cerebrospinal fluid glial fibrillary acidic protein levels in adults with Down syndrome: a longitudinal cohort study","volume":"90","author":"Montoliu-Gaya","year":"2023","journal-title":"EBioMedicine"},{"key":"10.1016\/j.lanhl.2024.07.013_bib43","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1136\/jnnp-2022-329663","article-title":"Plasma GFAP in presymptomatic and symptomatic familial Alzheimer\u2019s disease: a longitudinal cohort study","volume":"94","author":"O\u2019Connor","year":"2023","journal-title":"J\u00a0Neurol Neurosurg Psychiatry"},{"key":"10.1016\/j.lanhl.2024.07.013_bib44","doi-asserted-by":"crossref","first-page":"1775","DOI":"10.1038\/s41591-023-02380-x","article-title":"Astrocyte reactivity influences amyloid-\u03b2 effects on tau pathology in preclinical Alzheimer\u2019s disease","volume":"29","author":"Bellaver","year":"2023","journal-title":"Nat Med"},{"key":"10.1016\/j.lanhl.2024.07.013_bib45","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1093\/brain\/awae035","article-title":"Serum GFAP levels correlate with astrocyte reactivity, post-mortem brain atrophy and neurofibrillary tangles","volume":"147","author":"S\u00e1nchez-Juan","year":"2024","journal-title":"Brain"},{"key":"10.1016\/j.lanhl.2024.07.013_bib46","doi-asserted-by":"crossref","first-page":"782","DOI":"10.1016\/S1474-4422(18)30231-X","article-title":"Serum GFAP and UCH-L1 for prediction of absence of intracranial injuries on head CT (ALERT-TBI): a multicentre observational study","volume":"17","author":"Bazarian","year":"2018","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.lanhl.2024.07.013_bib47","doi-asserted-by":"crossref","first-page":"E823","DOI":"10.1097\/BRS.0000000000000654","article-title":"Diagnostic value of serum levels of GFAP, pNF-H, and NSE compared with clinical findings in severity assessment of human traumatic spinal cord injury","volume":"40","author":"Ahadi","year":"2015","journal-title":"Spine"},{"key":"10.1016\/j.lanhl.2024.07.013_bib48","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1177\/1352458518819380","article-title":"Serum glial fibrillary acidic protein correlates with multiple sclerosis disease severity","volume":"26","author":"H\u00f6gel","year":"2020","journal-title":"Mult Scler"},{"key":"10.1016\/j.lanhl.2024.07.013_bib49","doi-asserted-by":"crossref","first-page":"e1299","DOI":"10.1212\/WNL.0000000000008160","article-title":"Serum GFAP and neurofilament light as biomarkers of disease activity and disability in NMOSD","volume":"93","author":"Watanabe","year":"2019","journal-title":"Neurology"},{"key":"10.1016\/j.lanhl.2024.07.013_bib50","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.3233\/JAD-200608","article-title":"Serum glial fibrillary acidic protein (GFAP) is a marker of disease severity in frontotemporal lobar degeneration","volume":"77","author":"Benussi","year":"2020","journal-title":"J\u00a0Alzheimers Dis"},{"key":"10.1016\/j.lanhl.2024.07.013_bib51","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1136\/jnnp-2019-321954","article-title":"Plasma glial fibrillary acidic protein is raised in progranulin-associated frontotemporal dementia","volume":"91","author":"Heller","year":"2020","journal-title":"J\u00a0Neurol Neurosurg Psychiatry"},{"key":"10.1016\/j.lanhl.2024.07.013_bib52","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1186\/s40035-021-00275-w","article-title":"Plasma glial fibrillary acidic protein and neurofilament light chain for the diagnostic and prognostic evaluation of frontotemporal dementia","volume":"10","author":"Zhu","year":"2021","journal-title":"Transl Neurodegener"},{"key":"10.1016\/j.lanhl.2024.07.013_bib53","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1016\/j.clineuro.2011.11.002","article-title":"Correlational study of the serum levels of the glial fibrillary acidic protein and neurofilament proteins in Parkinson\u2019s disease patients","volume":"114","author":"Su","year":"2012","journal-title":"Clin Neurol Neurosurg"},{"key":"10.1016\/j.lanhl.2024.07.013_bib54","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1002\/acn3.51708","article-title":"Serum levels of glial fibrillary acidic protein in patients with amyotrophic lateral sclerosis","volume":"10","author":"Verde","year":"2023","journal-title":"Ann Clin Transl Neurol"},{"key":"10.1016\/j.lanhl.2024.07.013_bib55","article-title":"Association of plasma glial fibrillary acidic protein (GFAP) with neuroimaging of Alzheimer\u2019s disease and vascular pathology","volume":"14","author":"Shir","year":"2022","journal-title":"Alzheimers Dement (Amst)"},{"key":"10.1016\/j.lanhl.2024.07.013_bib56","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1007\/s00702-022-02474-9","article-title":"Blood amyloid and tau biomarkers as predictors of cerebrospinal fluid profiles","volume":"129","author":"Delaby","year":"2022","journal-title":"J\u00a0Neural Transm (Vienna)"},{"key":"10.1016\/j.lanhl.2024.07.013_bib57","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1016\/j.jalz.2017.06.2266","article-title":"Amyloid \u03b2 concentrations and stable isotope labeling kinetics of human plasma specific to central nervous system amyloidosis","volume":"13","author":"Ovod","year":"2017","journal-title":"Alzheimers Dement"},{"key":"10.1016\/j.lanhl.2024.07.013_bib58","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1186\/s13024-021-00451-6","article-title":"A\u00a0blood-based diagnostic test incorporating plasma A\u03b242\/40 ratio, ApoE proteotype, and age accurately identifies brain amyloid status: findings from a multi cohort validity analysis","volume":"16","author":"West","year":"2021","journal-title":"Mol Neurodegener"},{"key":"10.1016\/j.lanhl.2024.07.013_bib59","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1001\/jamaneurol.2019.0765","article-title":"Association between longitudinal plasma neurofilament light and neurodegeneration in patients with Alzheimer disease","volume":"76","author":"Mattsson","year":"2019","journal-title":"JAMA Neurol"},{"key":"10.1016\/j.lanhl.2024.07.013_bib60","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1038\/s41591-018-0304-3","article-title":"Serum neurofilament dynamics predicts neurodegeneration and clinical progression in presymptomatic Alzheimer\u2019s disease","volume":"25","author":"Preische","year":"2019","journal-title":"Nat Med"},{"key":"10.1016\/j.lanhl.2024.07.013_bib61","doi-asserted-by":"crossref","first-page":"2790","DOI":"10.1002\/alz.12879","article-title":"Plasma glial fibrillary acidic protein in autosomal dominant Alzheimer\u2019s disease: associations with A\u03b2-PET, neurodegeneration, and cognition","volume":"19","author":"Chatterjee","year":"2023","journal-title":"Alzheimers Dement"},{"key":"10.1016\/j.lanhl.2024.07.013_bib62","author":"Huber"},{"key":"10.1016\/j.lanhl.2024.07.013_bib63","doi-asserted-by":"crossref","first-page":"2340","DOI":"10.1002\/alz.13697","article-title":"Biomarkers of Alzheimer\u2019s disease and neurodegeneration in dried blood spots\u2014a new collection method for remote settings","volume":"20","author":"Huber","year":"2024","journal-title":"Alzheimers Dement"},{"key":"10.1016\/j.lanhl.2024.07.013_bib64","first-page":"434","article-title":"Population-based blood screening for preclinical Alzheimer\u2019s disease in a British birth cohort at age 70","volume":"144","author":"Keshavan","year":"2021","journal-title":"Brain"},{"key":"10.1016\/j.lanhl.2024.07.013_bib65","doi-asserted-by":"crossref","DOI":"10.1016\/j.drudis.2024.103911","article-title":"Cost-effectiveness comparison between blood biomarkers and conventional tests in Alzheimer\u2019s disease diagnosis","volume":"29","author":"Noda","year":"2024","journal-title":"Drug Discov Today"},{"key":"10.1016\/j.lanhl.2024.07.013_bib66","article-title":"Blood-based biomarkers for Alzheimer\u2019s pathology and the diagnostic process for a disease-modifying treatment: projecting the impact on the cost and wait times","volume":"12","author":"Mattke","year":"2020","journal-title":"Alzheimers Dement (Amst)"},{"key":"10.1016\/j.lanhl.2024.07.013_bib67","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1016\/j.jalz.2013.01.010","article-title":"CSF biomarker variability in the Alzheimer\u2019s Association quality control program","volume":"9","author":"Mattsson","year":"2013","journal-title":"Alzheimers Dement"},{"key":"10.1016\/j.lanhl.2024.07.013_bib68","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0100784","article-title":"Variability of CSF Alzheimer\u2019s disease biomarkers: implications for clinical practice","volume":"9","author":"Vos","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.lanhl.2024.07.013_bib69","doi-asserted-by":"crossref","first-page":"1575","DOI":"10.1002\/alz.12316","article-title":"The Alzheimer\u2019s Association international guidelines for handling of cerebrospinal fluid for routine clinical measurements of amyloid \u03b2 and tau","volume":"17","author":"Hansson","year":"2021","journal-title":"Alzheimers Dement"},{"key":"10.1016\/j.lanhl.2024.07.013_bib70","doi-asserted-by":"crossref","first-page":"1484","DOI":"10.1002\/alz.12510","article-title":"Characterization of pre-analytical sample handling effects on a panel of Alzheimer\u2019s disease\u2013related blood-based biomarkers: results from the Standardization of Alzheimer\u2019s Blood Biomarkers (SABB) working group","volume":"18","author":"Verberk","year":"2022","journal-title":"Alzheimers Dement"},{"key":"10.1016\/j.lanhl.2024.07.013_bib71","doi-asserted-by":"crossref","first-page":"5531","DOI":"10.1002\/alz.13163","article-title":"Levels of Alzheimer\u2019s disease blood biomarkers are altered after food intake\u2014a pilot intervention study in healthy adults","volume":"19","author":"Huber","year":"2023","journal-title":"Alzheimers Dement"},{"key":"10.1016\/j.lanhl.2024.07.013_bib72","first-page":"133","article-title":"Physical activity and amyloid beta in middle-aged and older adults: a systematic review and meta-analysis","volume":"13","author":"Rodriguez-Ayllon","year":"2024","journal-title":"J\u00a0Sport Heal Sci"},{"key":"10.1016\/j.lanhl.2024.07.013_bib73","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1186\/s13195-024-01391-1","article-title":"Effects of certain pre-analytical factors on the performance of plasma phospho-tau217","volume":"16","author":"Bali","year":"2024","journal-title":"Alzheimers Res Ther"},{"key":"10.1016\/j.lanhl.2024.07.013_bib74","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1016\/j.dadm.2018.08.006","article-title":"Diagnostic performance of Elecsys immunoassays for cerebrospinal fluid Alzheimer\u2019s disease biomarkers in a nonacademic, multicenter memory clinic cohort: the ABIDE project","volume":"10","author":"Willemse","year":"2018","journal-title":"Alzheimers Dement (Amst)"},{"key":"10.1016\/j.lanhl.2024.07.013_bib75","doi-asserted-by":"crossref","first-page":"1493","DOI":"10.1002\/alz.12145","article-title":"First amyloid \u03b21-42\u00a0certified reference material for re-calibrating commercial immunoassays","volume":"16","author":"Boulo","year":"2020","journal-title":"Alzheimers Dement"},{"key":"10.1016\/j.lanhl.2024.07.013_bib76","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1186\/s13195-021-00939-9","article-title":"Clinical and analytical comparison of six Simoa assays for plasma P-tau isoforms P-tau181, P-tau217, and P-tau231","volume":"13","author":"Bayoumy","year":"2021","journal-title":"Alzheimers Res Ther"},{"key":"10.1016\/j.lanhl.2024.07.013_bib77","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.1515\/cclm-2022-1181","article-title":"Assessing the commutability of candidate reference materials for the harmonization of neurofilament light measurements in blood","volume":"61","author":"Andreasson","year":"2023","journal-title":"Clin Chem Lab Med"},{"key":"10.1016\/j.lanhl.2024.07.013_bib78","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1016\/j.dadm.2019.02.002","article-title":"Preanalytical sample handling recommendations for Alzheimer\u2019s disease plasma biomarkers","volume":"11","author":"R\u00f3zga","year":"2019","journal-title":"Alzheimers Dement (Amst)"},{"key":"10.1016\/j.lanhl.2024.07.013_bib79","doi-asserted-by":"crossref","first-page":"1580","DOI":"10.1515\/cclm-2023-0245","article-title":"Effects of storage conditions on the stability of blood-based markers for the diagnosis of Alzheimer\u2019s disease","volume":"61","author":"Mansilla","year":"2023","journal-title":"Clin Chem Lab Med"},{"key":"10.1016\/j.lanhl.2024.07.013_bib80","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/S1474-4422(21)00361-6","article-title":"Blood-based biomarkers for Alzheimer\u2019s disease: towards clinical implementation","volume":"21","author":"Teunissen","year":"2022","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.lanhl.2024.07.013_bib81","doi-asserted-by":"crossref","first-page":"1398","DOI":"10.1038\/s41591-022-01822-2","article-title":"Performance of plasma phosphorylated tau 181\u00a0and 217\u00a0in the community","volume":"28","author":"Mielke","year":"2022","journal-title":"Nat Med"},{"key":"10.1016\/j.lanhl.2024.07.013_bib82","doi-asserted-by":"crossref","first-page":"e277","DOI":"10.1212\/WNL.0000000000207419","article-title":"Association of chronic kidney disease with plasma NfL and other biomarkers of neurodegeneration: the H70 Birth Cohort Study in Gothenburg","volume":"101","author":"Dittrich","year":"2023","journal-title":"Neurology"},{"key":"10.1016\/j.lanhl.2024.07.013_bib83","doi-asserted-by":"crossref","first-page":"1403","DOI":"10.1002\/alz.12787","article-title":"Confounding factors of Alzheimer\u2019s disease plasma biomarkers and their impact on clinical performance","volume":"19","author":"Pichet Binette","year":"2023","journal-title":"Alzheimers Dement"},{"key":"10.1016\/j.lanhl.2024.07.013_bib84","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1001\/jamaneurol.2023.0199","article-title":"Mitigating the associations of kidney dysfunction with blood biomarkers of Alzheimer disease by using phosphorylated tau to total tau ratios","volume":"80","author":"Janelidze","year":"2023","journal-title":"JAMA Neurol"},{"key":"10.1016\/j.lanhl.2024.07.013_bib85","doi-asserted-by":"crossref","first-page":"1128","DOI":"10.1002\/alz.12466","article-title":"Associations of amyloid and neurodegeneration plasma biomarkers with comorbidities","volume":"18","author":"Syrjanen","year":"2022","journal-title":"Alzheimers Dement"},{"key":"10.1016\/j.lanhl.2024.07.013_bib86","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1001\/jamaneurol.2023.0050","article-title":"Alzheimer disease blood biomarkers in patients with out-of-hospital cardiac arrest","volume":"80","author":"Ashton","year":"2023","journal-title":"JAMA Neurol"},{"key":"10.1016\/j.lanhl.2024.07.013_bib87","doi-asserted-by":"crossref","first-page":"1063","DOI":"10.1001\/jamaneurol.2017.0655","article-title":"Comparing plasma phospho tau, total tau, and phospho tau\u2013total tau ratio as acute and chronic traumatic brain injury biomarkers","volume":"74","author":"Rubenstein","year":"2017","journal-title":"JAMA Neurol"},{"key":"10.1016\/j.lanhl.2024.07.013_bib88","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1001\/jamaneurol.2023.4719","article-title":"Effect of neprilysin inhibition on Alzheimer disease plasma biomarkers: a secondary analysis of a randomized clinical trial","volume":"81","author":"Brum","year":"2024","journal-title":"JAMA Neurol"},{"key":"10.1016\/j.lanhl.2024.07.013_bib89","doi-asserted-by":"crossref","first-page":"1231","DOI":"10.1136\/jnnp-2021-327370","article-title":"Blood-based high sensitivity measurements of beta-amyloid and phosphorylated tau as biomarkers of Alzheimer\u2019s disease: a focused review on recent advances","volume":"92","author":"Chong","year":"2021","journal-title":"J\u00a0Neurol Neurosurg Psychiatry"},{"key":"10.1016\/j.lanhl.2024.07.013_bib90","first-page":"355","article-title":"Plasma biomarkers of Alzheimer\u2019s disease: a review of available assays, recent developments, and implications for clinical practice","volume":"7","author":"Pais","year":"2023","journal-title":"J\u00a0Alzheimers Dis Rep"},{"key":"10.1016\/j.lanhl.2024.07.013_bib91","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.1002\/alz.12301","article-title":"Plasma p-tau181, p-tau217, and other blood-based Alzheimer\u2019s disease biomarkers in a multi-ethnic, community study","volume":"17","author":"Brickman","year":"2021","journal-title":"Alzheimers Dement"},{"key":"10.1016\/j.lanhl.2024.07.013_bib92","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1002\/alz.12647","article-title":"Medical comorbidities and ethnicity impact plasma Alzheimer\u2019s disease biomarkers: important considerations for clinical trials and practice","volume":"19","author":"O\u2019Bryant","year":"2023","journal-title":"Alzheimers Dement"},{"key":"10.1016\/j.lanhl.2024.07.013_bib93","doi-asserted-by":"crossref","first-page":"e245","DOI":"10.1212\/WNL.0000000000200358","article-title":"Effect of race on prediction of brain amyloidosis by plasma A\u03b242\/A\u03b240, phosphorylated tau, and neurofilament light","volume":"99","author":"Schindler","year":"2022","journal-title":"Neurology"},{"key":"10.1016\/j.lanhl.2024.07.013_bib94","article-title":"Brain atrophy and white matter hyperintensities are independently associated with plasma neurofilament light chain in an Asian cohort of cognitively impaired patients with concomitant cerebral small vessel disease","volume":"15","author":"Chong","year":"2023","journal-title":"Alzheimers Dement (Amst)"},{"key":"10.1016\/j.lanhl.2024.07.013_bib95","doi-asserted-by":"crossref","first-page":"1649","DOI":"10.1002\/alz.12332","article-title":"Plasma p-tau181 to A\u03b242 ratio is associated with brain amyloid burden and hippocampal atrophy in an Asian cohort of Alzheimer\u2019s disease patients with concomitant cerebrovascular disease","volume":"17","author":"Chong","year":"2021","journal-title":"Alzheimers Dement"},{"key":"10.1016\/j.lanhl.2024.07.013_bib96","doi-asserted-by":"crossref","first-page":"1800","DOI":"10.1016\/j.scib.2023.07.009","article-title":"Blood-based biomarkers for Alzheimer\u2019s disease: a multicenter-based cross-sectional and longitudinal study in China","volume":"68","author":"Gao","year":"2023","journal-title":"Sci Bull"},{"key":"10.1016\/j.lanhl.2024.07.013_bib97","doi-asserted-by":"crossref","first-page":"e1402","DOI":"10.1212\/WNL.0000000000207675","article-title":"Association of plasma biomarkers of Alzheimer disease with cognition and medical comorbidities in a biracial cohort","volume":"101","author":"Ramanan","year":"2023","journal-title":"Neurology"},{"key":"10.1016\/j.lanhl.2024.07.013_bib98","doi-asserted-by":"crossref","first-page":"4314","DOI":"10.1038\/s41380-022-01675-8","article-title":"Sex differences in plasma p-tau181 associations with Alzheimer\u2019s disease biomarkers, cognitive decline, and clinical progression","volume":"27","author":"Tsiknia","year":"2022","journal-title":"Mol Psychiatry"},{"key":"10.1016\/j.lanhl.2024.07.013_bib99","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1002\/alz.13454","article-title":"Plasma phosphorylated tau-217\u00a0exhibits sex-specific prognostication of cognitive decline and brain atrophy in cognitively unimpaired adults","volume":"20","author":"Saloner","year":"2024","journal-title":"Alzheimers Dement"},{"key":"10.1016\/j.lanhl.2024.07.013_bib100","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2023.101860","article-title":"Global and regional prevalence of multimorbidity in the adult population in community settings: a systematic review and meta-analysis","volume":"57","author":"Chowdhury","year":"2023","journal-title":"EClinicalMedicine"},{"key":"10.1016\/j.lanhl.2024.07.013_bib101","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1093\/gerona\/glv128","article-title":"Global multimorbidity patterns: a cross-sectional, population-based, multi-country study","volume":"71","author":"Garin","year":"2016","journal-title":"J\u00a0Gerontol A\u00a0Biol Sci Med Sci"},{"key":"10.1016\/j.lanhl.2024.07.013_bib102","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-021-90746-x","article-title":"High burden of cerebral white matter lesion in 9\u00a0Asian cities","volume":"11","author":"Lam","year":"2021","journal-title":"Sci Rep"},{"key":"10.1016\/j.lanhl.2024.07.013_bib103","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1111\/joim.12495","article-title":"Alzheimer\u2019s disease with cerebrovascular disease: current status in the Asia\u2013Pacific region","volume":"280","author":"Chen","year":"2016","journal-title":"J\u00a0Intern Med"},{"key":"10.1016\/j.lanhl.2024.07.013_bib104","doi-asserted-by":"crossref","first-page":"967","DOI":"10.3233\/JAD-215730","article-title":"Blood tests for Alzheimer\u2019s disease: increasing efforts to expand and diversify research participation is critical for widespread validation and acceptance","volume":"90","author":"Karikari","year":"2022","journal-title":"J\u00a0Alzheimers Dis"},{"key":"10.1016\/j.lanhl.2024.07.013_bib105","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1016\/S1474-4422(17)30159-X","article-title":"Strategic roadmap for an early diagnosis of Alzheimer\u2019s disease based on biomarkers","volume":"16","author":"Frisoni","year":"2017","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.lanhl.2024.07.013_bib106","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1002\/alz.12724","article-title":"Plasma A\u03b242\/40 ratio, p-tau181, GFAP, and NfL across the Alzheimer\u2019s disease continuum: a cross-sectional and longitudinal study in the AIBL cohort","volume":"19","author":"Chatterjee","year":"2023","journal-title":"Alzheimers Dement"},{"key":"10.1016\/j.lanhl.2024.07.013_bib107","doi-asserted-by":"crossref","DOI":"10.1093\/braincomms\/fcaa041","article-title":"Longitudinal evaluation of the natural history of amyloid-\u03b2 in plasma and brain","volume":"2","author":"Burnham","year":"2020","journal-title":"Brain Commun"},{"key":"10.1016\/j.lanhl.2024.07.013_bib108","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1093\/brain\/awaa399","article-title":"Time course of phosphorylated-tau181 in blood across the Alzheimer\u2019s disease spectrum","volume":"144","author":"Moscoso","year":"2021","journal-title":"Brain"},{"key":"10.1016\/j.lanhl.2024.07.013_bib109","doi-asserted-by":"crossref","first-page":"2555","DOI":"10.1038\/s41591-022-02074-w","article-title":"Differential roles of A\u03b242\/40, p-tau231 and p-tau217 for Alzheimer\u2019s trial selection and disease monitoring","volume":"28","author":"Ashton","year":"2022","journal-title":"Nat Med"},{"key":"10.1016\/j.lanhl.2024.07.013_bib110","doi-asserted-by":"crossref","first-page":"5967","DOI":"10.1038\/s41380-020-0838-x","article-title":"Plasma phospho-tau181 in presymptomatic and symptomatic familial Alzheimer\u2019s disease: a longitudinal cohort study","volume":"26","author":"O\u2019Connor","year":"2021","journal-title":"Mol Psychiatry"},{"key":"10.1016\/j.lanhl.2024.07.013_bib111","doi-asserted-by":"crossref","first-page":"952","DOI":"10.3390\/medicina58070952","article-title":"Biomarkers for Alzheimer\u2019s disease: context of use, qualification, and roadmap for clinical implementation","volume":"58","author":"Cummings","year":"2022","journal-title":"Medicina (Kaunas)"},{"key":"10.1016\/j.lanhl.2024.07.013_bib112","doi-asserted-by":"crossref","first-page":"2669","DOI":"10.1002\/alz.12756","article-title":"The Alzheimer\u2019s Association appropriate use recommendations for blood biomarkers in Alzheimer\u2019s disease","volume":"18","author":"Hansson","year":"2022","journal-title":"Alzheimers Dement"},{"key":"10.1016\/j.lanhl.2024.07.013_bib113","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1038\/s43856-023-00295-9","article-title":"Integrated algorithm combining plasma biomarkers and cognitive assessments accurately predicts brain \u03b2-amyloid pathology","volume":"3","author":"Pan","year":"2023","journal-title":"Commun Med (Lond)"},{"key":"10.1016\/j.lanhl.2024.07.013_bib114","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1186\/s13195-022-00990-0","article-title":"Combining plasma phospho-tau and accessible measures to evaluate progression to Alzheimer\u2019s dementia in mild cognitive impairment patients","volume":"14","author":"Pichet Binette","year":"2022","journal-title":"Alzheimers Res Ther"},{"key":"10.1016\/j.lanhl.2024.07.013_bib115","author":"George"},{"key":"10.1016\/j.lanhl.2024.07.013_bib116","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1001\/jamaneurol.2022.2379","article-title":"Association of elevated amyloid and tau positron emission tomography signal with near-term development of Alzheimer disease symptoms in older adults without cognitive impairment","volume":"79","author":"Strikwerda-Brown","year":"2022","journal-title":"JAMA Neurol"},{"key":"10.1016\/j.lanhl.2024.07.013_bib117","doi-asserted-by":"crossref","first-page":"2381","DOI":"10.1038\/s41591-022-02049-x","article-title":"Amyloid and tau PET-positive cognitively unimpaired individuals are at high risk for future cognitive decline","volume":"28","author":"Ossenkoppele","year":"2022","journal-title":"Nat Med"},{"key":"10.1016\/j.lanhl.2024.07.013_bib118","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1016\/S1474-4422(21)00066-1","article-title":"Clinical diagnosis of Alzheimer\u2019s disease: recommendations of the International Working Group","volume":"20","author":"Dubois","year":"2021","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.lanhl.2024.07.013_bib119","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1016\/j.jalz.2016.02.002","article-title":"Preclinical Alzheimer\u2019s disease: definition, natural history, and diagnostic criteria","volume":"12","author":"Dubois","year":"2016","journal-title":"Alzheimers Dement"},{"key":"10.1016\/j.lanhl.2024.07.013_bib120","first-page":"142","article-title":"Donanemab in early Alzheimer\u2019s disease","volume":"22","author":"Riederer","year":"2021","journal-title":"J\u00a0Neurol Neurochir Psychiatr"},{"key":"10.1016\/j.lanhl.2024.07.013_bib121","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1001\/jama.2023.13239","article-title":"Donanemab in early symptomatic Alzheimer disease: the TRAILBLAZER-ALZ 2\u00a0randomized clinical trial","volume":"330","author":"Sims","year":"2023","journal-title":"JAMA"},{"key":"10.1016\/j.lanhl.2024.07.013_bib124","doi-asserted-by":"crossref","first-page":"2614","DOI":"10.1002\/alz.12570","article-title":"CSF biomarkers and plasma p-tau181 as predictors of longitudinal tau accumulation: implications for clinical trial design","volume":"18","author":"Moscoso","year":"2022","journal-title":"Alzheimers Dement"},{"key":"10.1016\/j.lanhl.2024.07.013_bib125","doi-asserted-by":"crossref","first-page":"1175","DOI":"10.1002\/alz.12754","article-title":"Using Alzheimer\u2019s disease blood tests to accelerate clinical trial enrollment","volume":"19","author":"Schindler","year":"2023","journal-title":"Alzheimers Dement"},{"key":"10.1016\/j.lanhl.2024.07.013_bib126","doi-asserted-by":"crossref","first-page":"1060","DOI":"10.1001\/jamaneurol.2019.1632","article-title":"Performance of fully automated plasma assays as screening tests for Alzheimer disease\u2013related \u03b2-amyloid status","volume":"76","author":"Palmqvist","year":"2019","journal-title":"JAMA Neurol"},{"key":"10.1016\/j.lanhl.2024.07.013_bib127","doi-asserted-by":"crossref","first-page":"1691","DOI":"10.1056\/NEJMoa2100708","article-title":"Donanemab in early Alzheimer\u2019s disease","volume":"384","author":"Mintun","year":"2021","journal-title":"N\u00a0Engl J\u00a0Med"},{"key":"10.1016\/j.lanhl.2024.07.013_bib128","doi-asserted-by":"crossref","first-page":"1954","DOI":"10.1038\/s41591-023-02443-z","article-title":"CSF MTBR-tau243 is a specific biomarker of tau tangle pathology in Alzheimer\u2019s disease","volume":"29","author":"Horie","year":"2023","journal-title":"Nat Med"},{"key":"10.1016\/j.lanhl.2024.07.013_bib129","doi-asserted-by":"crossref","first-page":"1250","DOI":"10.1001\/jamaneurol.2022.3392","article-title":"Association of donanemab treatment with exploratory plasma biomarkers in early symptomatic Alzheimer disease: a secondary analysis of the TRAILBLAZER-ALZ randomized clinical trial","volume":"79","author":"Pontecorvo","year":"2022","journal-title":"JAMA Neurol"},{"key":"10.1016\/j.lanhl.2024.07.013_bib130","first-page":"362","article-title":"Lecanemab: appropriate use recommendations","volume":"10","author":"Cummings","year":"2023","journal-title":"J\u00a0Prev Alzheimers Dis"},{"key":"10.1016\/j.lanhl.2024.07.013_bib131","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1016\/j.jalz.2018.02.018","article-title":"NIA-AA Research Framework: toward a biological definition of Alzheimer\u2019s disease","volume":"14","author":"Jack","year":"2018","journal-title":"Alzheimers Dement"},{"key":"10.1016\/j.lanhl.2024.07.013_bib132","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1038\/s43587-023-00404-2","article-title":"Towards a future where Alzheimer\u2019s disease pathology is stopped before the onset of dementia","volume":"3","author":"van der Flier","year":"2023","journal-title":"Nat Aging"},{"key":"10.1016\/j.lanhl.2024.07.013_bib133","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1001\/jamaneurol.2020.4835","article-title":"The future is P-tau-anticipating direct-to-consumer Alzheimer disease blood tests","volume":"78","author":"Largent","year":"2021","journal-title":"JAMA Neurol"},{"key":"10.1016\/j.lanhl.2024.07.013_bib134","doi-asserted-by":"crossref","first-page":"2781","DOI":"10.1016\/j.neuron.2023.05.017","article-title":"Blood-based biomarkers for Alzheimer\u2019s disease: current state and future use in a transformed global healthcare landscape","volume":"111","author":"Hampel","year":"2023","journal-title":"Neuron"},{"key":"10.1016\/j.lanhl.2024.07.013_bib135","doi-asserted-by":"crossref","DOI":"10.1002\/alz.079187","article-title":"REAL AD\u2013a realistic screening approach for preclinical Alzheimer\u2019s disease","volume":"19","author":"Blennow","year":"2023","journal-title":"Alzheimers Dement"},{"key":"10.1016\/j.lanhl.2024.07.013_bib136","doi-asserted-by":"crossref","DOI":"10.1093\/braincomms\/fcae151","article-title":"Quantification of neurofilament light and glial fibrillary acidic protein in finger-prick blood","volume":"6","author":"Kolanko","year":"2024","journal-title":"Brain Commun"}],"container-title":["The Lancet Healthy Longevity"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S266675682400148X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S266675682400148X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,11,14]],"date-time":"2024-11-14T16:54:43Z","timestamp":1731603283000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S266675682400148X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10]]},"references-count":134,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2024,10]]}},"alternative-id":["S266675682400148X"],"URL":"https:\/\/doi.org\/10.1016\/j.lanhl.2024.07.013","relation":{},"ISSN":["2666-7568"],"issn-type":[{"value":"2666-7568","type":"print"}],"subject":[],"published":{"date-parts":[[2024,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Challenges in the practical implementation of blood biomarkers for Alzheimer\u2019s disease","name":"articletitle","label":"Article Title"},{"value":"The Lancet Healthy Longevity","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.lanhl.2024.07.013","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Author(s). Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"100630"}}